| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/PPO.0B013E31815A7C0A |
| P698 | PubMed publication ID | 18032975 |
| P2093 | author name string | Francisco Cervantes | |
| Giovanni Barosi | |||
| Ruben Mesa | |||
| P433 | issue | 6 | |
| P921 | main subject | myelofibrosis | Q1752571 |
| chronic idiopathic myelofibrosis | Q3857106 | ||
| P304 | page(s) | 377-383 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | The Cancer Journal | Q2589130 |
| P1476 | title | New and old treatment modalities in primary myelofibrosis | |
| P478 | volume | 13 |
| Q46570218 | 5-Azacitidine has limited therapeutic activity in myelofibrosis |
| Q81706300 | A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis |
| Q64250444 | Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options |
| Q46729368 | Bortezomib therapy in myelofibrosis: a phase II clinical trial |
| Q37191213 | CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin |
| Q44041669 | Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults |
| Q40297890 | Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent |
| Q39255427 | Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. |
| Q37815421 | Deactylase inhibition in myeloproliferative neoplasms |
| Q38143243 | Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis |
| Q33915577 | Evidence for organ-specific stem cell microenvironments |
| Q33406694 | Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis. |
| Q46436942 | Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject |
| Q33401615 | Immunomodulatory agents in myelofibrosis |
| Q37521986 | In vitro evaluation of the efficacy of liposomal and pegylated liposomal hydroxyurea |
| Q34150008 | JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations |
| Q37472874 | Kinase drug discovery approaches in chronic myeloproliferative disorders |
| Q33517074 | Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years |
| Q38613880 | Myeloproliferative neoplasms: A decade of discoveries and treatment advances |
| Q37956603 | Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management |
| Q38076672 | Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management |
| Q50462637 | Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management |
| Q39015300 | Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management |
| Q35427915 | Profile of pomalidomide and its potential in the treatment of myelofibrosis |
| Q36949506 | Removal of the spleen in mice alters the cytokine expression profile of the marrow micro-environment and increases bone formation |
| Q83734931 | The stromal composition of mast cell aggregates in systemic mastocytosis |
| Q35988523 | Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase |
Search more.